GSK Wellbutrin XL Approval Pressures Generics to Launch SR Formulation
Executive Summary
The approval of GlaxoSmithKline's Wellbutrin XL puts pressure on generic firms to launch their sustained-release versions of the antidepressant
You may also be interested in...
GSK Wellbutrin Metabolite, Advair Successor In Phase II; NDAs In 2006-2008
GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004
GSK Wellbutrin Metabolite, Advair Successor In Phase II; NDAs In 2006-2008
GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004
Eon Wellbutrin SR Generic Launch Could Slow GSK Conversion Efforts
Eon's launch of generic bupropion extended-release (Wellbutrin SR) should allow it to grab significant market share before GlaxoSmithKline fully converts SR patients to once-daily Wellbutrin XL